399 Binney St., Suite 2, Cambridge MA 02142
City Therapeutics was founded in July 2023.
City Therapeutics, Inc. was incorporated under the laws of the State of Delaware.
City Therapeutics’ initial public offering was completed on October 16, 2026.
City Therapeutics’ common stock is traded on the NASDAQ Global Capital Market under the ticker symbol CTY.
City Therapeutics’ CUSIP number is 178782 108.
The Company’s fiscal year-end is December 31st.
City Therapeutics’ transfer agent is Computershare Trust Company, N.A. Please direct any inquiries or transaction requests to Computershare using the options below:
Website: www.computershare.com/us
Phone: +1 (800) 736-3001, option 1 (U.S) and +1 (781) 575-3100, option 1 (non U.S.)
Email: web.queries@computershare.com
By Mail: Computershare, P.O. Box 43006, Providence, RI 02940-3006
By Overnight Delivery: Computershare, 150 Royall Street, Suite 101, Canton, MA 02021
The Company currently does not have a direct stock purchase plan.
The Company’s independent auditor is PricewaterhouseCoopers LLP, and its outside corporate legal counsel is Goodwin Procter LLP.
City Therapeutics’ press releases can be viewed under the “News Releases” page of the “Investors” section of our corporate website and financial reports can be found under the “Financial Information” page of the “Investors” section on our website.
Our SEC Filings can be found on www.sec.gov and are also available under the “SEC Filings” page of the “Investors” section on our website.
Investor Relations can be reached at investors@citytx.com.
Please visit the “Email Alerts” page of the "Investors" section of City Therapeutics’ corporate website to be added to the Company’s distribution list.
The whistleblower/compliance can be accessed either online at https://www.whistleblowerservices.com/CITY or by calling 833-691-0949.